Therapeutics & Vaccines
Modified Retinoid Compounds with Reduced Toxicity
Inventors: Margaret Clagett-Dame, Hector DeLuca, Sumithra Gowlugari
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing retinoid esters that have been modified to be significantly less toxic than the parent retinoids and can be administered orally with minimal side effects.
Orally administered retinoic acid isomers are used to treat many disorders; however, they cause serious side effects including weight loss, inanition, eye encrustation, bone loss, mucocutaneous toxicity, hyperlipidemia and teratogenic activity in patients who are pregnant.
UW-Madison researchers have developed modified retinoid esters with reduced toxicity. The carboxyl group of a retinoid is esterified with a highly sterically hindered compound, preferably a secondary or tertiary alcohol. The resulting retinoid esters are significantly less toxic than the parent retinoids and can be administered orally with minimal side effects.
- Potentially useful for treating all diseases where retinoid compounds have been effective, including proliferative skin disorders, neoplastic diseases and skin conditions
- Resulting compounds can be administered orally
- Greatly reduces the risk of serious side effects typically associated with oral retinoid use
- Offer much greater therapeutic window than parent retinoids